Gastroenterology Panel Discussion about the use of SSIs for Crohn’s disease
Listen to this informative panel discussion about the use of site specific immunomodulators (SSIs), an investigational treatment aimed at stimulating the immune system to reverse the chronic
Podcast: The Natural Health Show Special Report on Crohn’s December 7th & 8th, 2013
Update December 10th - Podcast of the show now available. Listen here. ______ Tune into The Natural Health Show this weekend for a special report on the impact of Crohn's disease. Host Steve
Travel Subsidy Now Offered to Crohn’s Trial Participants
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system, announced that it has received ethics approval to
First Patient Enrolled in Phase 1/2 Crohn’s Clinical Trial
Vancouver, British Columbia – June 11, 2013 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system,
New IBD Advisory Team Formed
Vancouver, British Columbia – May 30, 2013 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune
Qu Biologics launches treatment trial for Crohn’s disease
Vancouver, BC – Canadian participants are being sought for a new Health Canada-approved clinical trial for the treatment of Crohn’s disease, the Vancouver-based biopharmaceutical company Qu